Letters to the EditorImpact of COVID- 19 Infection Among Hospitalized Amyotrophic Lateral Sclerosis PatientsDigala, Lakshmi P. MBBS*; Prasanna, Shivika MS†; Rao, Praveen PhD†; Govindarajan, Raghav MD*; Qureshi, Adnan I. MD*Author Information *Department of Neurology, University of Missouri Health Care, Columbia, MO †Departments of Health Management & Informatics, Center for Biomedical Informatics, Electrical Engineering & Computer Science, University of Missouri, Columbia, MO R. Govindarajan serves on the advisory board of Alexion Pharmaceuticals, Argenx Pharmaceuticals, Mitsubishi Tanabe Pharmaceuticals, Catalyst pharmaceuticals, Roche pharmaceuticals, Amicus pharmaceuticals, Sarepta pharmaceuticals and has received research support from Alexion Pharmaceuticals, Ra Pharmaceuticals, Strongbridge Pharmaceuticals, American Academy of Neurology, AMARC Enterprises/Poly-MVA, Dysimmune Foundation and InfuCare. He has received speaking honorarium from American Academy of Neurology, Alexion Pharmaceuticals, Mitsubishi Tanabe Pharmaceuticals, Catalyst Pharmaceuticals, Muscular Dystrophy Association and publication honorarium from Springer Publishing, USA, and royalties from CRC press. The remaining authors report no conflicts of interest. L.P. Digala and S. Prasanna are the equal contributors. Ethical Publication Statement: We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. Journal of Clinical Neuromuscular Disease: March 2021 - Volume 22 - Issue 3 - p 180-181 doi: 10.1097/CND.0000000000000335 Buy Metrics Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.